Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 122pembrolizumab 118Magnetic Resonance Spectroscopy 107Carboplatin 86Cyclophosphamide 75Biopsy 68Cisplatin 63Paclitaxel 58Bevacizumab 56Gemcitabine 49Nivolumab 47fludarabine 44Dexamethasone 39Rituximab 38Pemetrexed 38Fluorouracil 37atezolizumab 36Docetaxel 36Doxorubicin 34Radiotherapy 33Leucovorin 33venetoclax 31Oxaliplatin 30Capecitabine 30Temozolomide 28Prednisone 28Standard of Care 27Radiation 27Letrozole 27Cetuximab 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × sarilumab × 30 days × Clear all
NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07154290 2026-05-20

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Regeneron Pharmaceuticals

Phase 2 Recruiting
300 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡